Aileron Ventures Limited

Condensed Interim Financial Statements

For the three months ended March 31, 2012

(Unaudited)

Aileron Ventures Limited

Condensed Interim Financial Statements

For the three months ended March 31, 2012

(Unaudited)

Contents

	Page
Condensed Interim Statement of Financial Position	3
Condensed Interim Statement of Loss and Comprehensive Loss	4
Condensed Interim Statement of Changes in Shareholders' Equity	5
Condensed Interim Statement of Cash Flows	6
Notes to the Condensed Interim Financial Statements	7 – 11

Aileron Ventures Limited

(Incorporated under the laws of Alberta)

Statement of Financial Position

(expressed in Canadian dollars)

	Notes	March 31, 2012	December 31, 2011
Assets			
Current assets			
Cash		$ 243	$ 5,285
GST receivable		-	510
Investment	4	18,500	18,500
		$ 18,743	$ 24,295
Liabilities			
Current Liabilities			
Accounts payable and accrued liabilities		$ 2,490	$ 8,000
Due to affiliate	5	2,776	2,776
		5,266	10,776
Shareholder's Equity			
Share capital	6	27,770	27,770
Deficit		(14,293)	(14,251)
		13,477	13,519
		$ 18,743	$ 24,295

Approved by the Board, May 25, 2012

(signed) *"Harold Kunik"*, Director

(signed) *"John Mackay"*, Director

Aileron Ventures Limited

Statement of Loss and Comprehensive Loss

For the three months ended March 31

(expressed in Canadian dollars)

	2012	2011
Revenue	$ -	$ -
Expenses		
Bank Charges	42	26
Professional fees	-	7,250
	42	7,276
Net loss and comprehensive loss	$ (42)	$ (7,276)

Aileron Ventures Limited

Statement of Changes in Shareholders' Equity

(expressed in Canadian dollars)

	Number of Common Shares	Common Shares Stated Value	Deficit	Total Equity
As at January 1, 2011	8,700,000	25,000	(3,435)	21,565
Share issued	964,155	2,770	-	2,770
Net loss	-	-	(7,276)	(7,276)
As at March 31, 2011	9,664,155	27,770	(10,711)	17,059
As at January 1, 2012	9,964,155	27,770	(14,251)	13,519
Net loss	-	-	(42)	(42)
As at March 31, 2012	9,964,155	$ 27,770	$ (14,293)	$ 13,477

Aileron Ventures Limited

Statements of Cash Flows

For the three months ended March 31

(shown in Canadian dollars)

	2012	2011
Net loss	$ (42)	$ (7,276)
Changes in non-cash working capital		
Accounts receivable	-	(476)
GST Receivable	510	
Accounts payable and accrued liabilities	(5,510)	(2,500)
Due to affiliate	-	(1,250)
	(5,042)	(11,502)
Investing activity		
Investment		(12,500)
Investment in affiliate	-	12,500
Change in cash and cash equivalents	(5,042)	(11,502)
Cash, beginning of period	5,285	12,500
Cash, end of period	$ 243	$ 998

1. General business description

Aileron Ventures Limited (the "Company" or "Aileron"), formerly 1539467 Alberta Ltd., was incorporated on May 31, 2010 under the Business Corporations Act (Alberta). To December 31, 2011, the only operations of the Company have been the investments (see note 4).

On January 11, 2011, the Company's affiliate, Altius, issued a joint management information circular and proxy statement relating to the proposed amalgamation of Altius and Immunall Science Inc. ("Immunall"). Under the terms of the proposed amalgamation, each Immunall shareholder received, for each common share of Immunall held, one common share in the amalgamated entity, 0.025 of a share in Aileron Ventures Limited and 0.025 of a share in Nautor Progressive Corporation. Each Aileron shareholder received, for each common share of Aileron held, one common share in the amalgamated entity. The proposed amalgamation was approved by shareholders and completed on March 31, 2011.

The address, and principal place of business of the Company is Suite 400, 2424 - 4th Street SW, Calgary, Alberta, Canada, T2S 2T4

2. Basis of preparation

(a) Statement of compliance

The condensed interim financial statements present Aileron's initial financial results of operations and financial position for the three months ended March 31, 2012.

The condensed interim financial statements have been prepared in accordance with International Accounting Standards ("IAS") 34, "Interim Financial Reporting". These condensed interim financial statements do not include all the necessary annual disclosures in accordance with IFRS.

A summary of the Company's significant accounting policies under IFRS is presented in note 3. These policies have been retrospectively and consistently applied except where specific exemptions permitted an alternative treatment upon transition to IFRS in accordance with IFRS 1.

The financial statements were approved for issue by the Board of Directors on May 25, 2012.

(b) Basis of measurement

The financial statements have been prepared on the historical cost basis except for the following:

(i) derivative financial instruments, if any, are measured at fair value; and
(ii) held for trading financial assets are measured at fair value with changes in fair value recorded in earnings.

The methods used to measure fair values are discussed in note 4 and 9(c).

(c) Functional and presentation currency

These financial statements are presented in Canadian dollars, which is the Company's functional currency.

(d) Use of estimates and judgments

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Judgments, estimates and underlying assumptions are reviewed on a continuous basis and are based on management's experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

In preparing our financial statements, we make judgments regarding the application of IFRS for our accounting policies. Significant judgments relate to valuation of investments and application of tax rules and regulations.

Information about significant areas of estimation uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes:

Note 4 - investment
Note 7 - Income tax expense

The following discussion sets forth management's most critical estimates and assumptions in determining the value of assets, liabilities and equity:

Investment

The investment is carried at fair value. Because the shares are not actively traded and the Company is not an active company, the investment has been valued based on a calculation of tangible asset backing.

Income taxes

The amounts recorded for deferred income taxes are based on estimates as to the timing of the reversal of temporary differences and tax rates currently substantively enacted. They are also based on estimates of the probability of the Company utilizing certain tax pools and assets which in turn are dependent on estimates of future taxable income. The availability of tax pools is subject to audit and interpretation by taxation authorities.

3. Significant accounting policies

These condensed interim financial statements have been prepared using the same accounting policies and methods of computation as the annual audited financial statements of Aileron for the year ended December 31, 2011. The disclosure contained in these condensed interim financial statements does not include all requirements in IAS 1, "Presentation of Financial Statements" ("IAS 1"). Accordingly, the condensed interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2011.

4. Investment

The investment is related to the conversion of the previous investment in affiliate (Altius) outlined in Note 1 to an investment in Immunall which represents a minority interest of approximately 4.5%. As the Company owns a minority position, the investment is accounted for as a held for sale financial asset, which is measured at fair value. At March 31, 2012, the fair value was $18,500.

5. Due to affiliate

The amount due to affiliate was $2,776 as of March 31, 2012 (December 31, 2011 $2,776), for legal fees and is unsecured and non-interest bearing.

6. Share capital

Authorized

Unlimited	Common voting shares
Unlimited	Preferred shares, issuable in series, with the rights, privileges, restrictions and conditions determined by the Board of Directors upon issuance

7. Income tax expense

Reconciliation of effective tax rate:

	2012	2011
Loss before income tax	$ (42)	$ (7,276)
Statutory tax rate	25.0%	26.5%
Expected income tax recovery	(11)	(1,928)
Tax losses not recognized	11	1,928
Total income tax recovery	$ -	$ -

Recognized deferred tax assets and liabilities:

Deferred tax assets and liabilities are attributable to the following:

	2012	2011
Deferred tax assets		
Non-capital losses	$ 11	$ 1,928
Less: Valuation allowance	(11)	(1,928)
Net deferred tax asset	$ -	$ -

The Company has available the following estimated non-capital loss carry forwards for which a deferred tax asset has not been recognized in the financial statements:

Year of Expiry	Amount
2030	$ 3,435
2031	$ 13,739
2032	$ 42

8. Capital disclosures

The Company's policy when managing capital is to maintain a strong capital base for the objectives of maintaining financial flexibility, creditor and market confidence and to sustain the future development of the business.

The Company includes shareholders' equity in the definition of capital.

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may adjust spending, issue new units or incur debt.

The Company has not changed its capital management policies during the year.

The Company is not subject to externally imposed capital requirements.

9. Financial instruments and risk management

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

The Company has the following financial instruments:

Cash and investment are designated as held-for-trading and are measured at fair value. Accounts receivable is classified as loans and receivables and accounts payable and accrued liabilities and due to affiliate are classified as other financial liabilities and are measured at amortized cost.

The Company is exposed to financial risk arising from its financial assets. The Company manages its exposure to financial risks in a manner that minimizes its exposure to the extent practical. The main financial risks affecting the Company are as follows:

(a) Credit risk

The financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash. The Company mitigates its exposure to credit loss by placing its cash with major financial institutions.

(b) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they are due. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due without incurring unacceptable losses or risking harm to the Company's reputation.

(c) Fair values

The fair value of cash, accounts payable and accrued liabilities and due to affiliate approximate their carrying value because of the short-term nature.

The fair value of transactions are classified according to the following hierarchy based on the amount of observable inputs used to value the instrument.

- Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 - Inputs are other than quoted prices in Level 1 that are either directly or indirectly observable for the asset or liability.
- Level 3 - Inputs for the asset or liability that are not based on observable market data.

Assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy level.

The Company's cash is transacted in active markets and has been classified using Level 1 inputs. The investment has been valued using Level 2 inputs.

10. Personnel expenses

There were no amounts paid to employees, officers or directors during the periods ended March 31, 2012 and 2011.